Salvage chemotherapy with oxaliplatin and capecitabine for breast cancer patients pretreated with anthracyclines and taxanes

Anticancer Research

Volumn 29, Issue 7, 2009, Pages 2851-2856

  Polyzos, Aristides ^a   Gogas, Helen ^a   Markopoulos, Christos ^a   Tsavaris, Nikolas ^a   Papadopoulos, Othon ^a   Polyzos, Kostas ^a   Giannopoulos, Athanasios ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Breast cancer chemotherapy; Capecitabine; Oxaliplatin

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; DEXAMETHASONE; ONDANSETRON; OXALIPLATIN; TAXANE DERIVATIVE;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BONE MARROW TOXICITY; BREAST ADENOCARCINOMA; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG POTENTIATION; DRUG TOLERABILITY; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; SALVAGE THERAPY; TAXOIDS;

EID: 69249184404     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Fossati R, Confalonieri C, Torri V, Ghislandi E, Penna A, Pistotti V, Tinazzi A and Liberati A: Cytotoxic and hormonal treatment for metastatic breast cancer: A systematic review of published randomized trials involving 31510 women. J Clin Oncol 16: 3439-3460, 1998. (Pubitemid 28481644)
2. Hortobagyi GN: Treatment of breast cancer. N Engl J Med 339: 974-984, 1998.
3. French Epirubicin Group: A prospective randomized phase III trial combination chemotherapy with cyclophosphamide, fluorouracil and either doxorubicin or epirubicin. J Clin Oncol 6: 679-688, 1988.
4. Buzdar AU, Asmar L and Hortobagyi GN: Impact of patient characteristics on treatment outcome: Anthracycline resistance. Eur J Cancer 33(suppl 7): S3-S6, 1997. (Pubitemid 127704322)
5. Porkka K, Blomqvist C, Rissamen P, Elomaa I and Pyzhönens S: Salvage therapies in women who fail to respond to first-line treatment with fluorouracil, epirubicin and cyclophosphamide for andvanced breast cancer. J Clin Oncol 12: 1639-1647, 1994. (Pubitemid 24245000)
6. Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, Buzdar AK, Frye DK and Hortobagyi GN: Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83: 1797 - 1805, 1991.
7. Reichman BS, Seidman AD, Crown JPA, Heelan R, Hakes TB, Lebwohl DE, Gilewski TA, Surbone A, Currie V and Hudis CA: Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 11: 1943-1951, 1993.
8. Wiserman L and Spencer CM: Paclitaxel: An update of its use in the treatment of metastatic breast cancer and ovarian and other gynaecological cancers. Drugs Aging 12: 305-334, 1998.
9. Seidman AD, Tiersten A, Hudis C, Gollup M, Barrett S, Yao TJ, Lepore J, Gilewski T, Currie V and Crown J: Phase II trial of paclitaxel by three-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol 13: 2575-2581, 1995.
10. Crown J: Phase III randomized trials of docetaxel in patients with metastatic breast cancer. Semin Oncol 26: 33-38, 1999. (Pubitemid 29314188)
11. Trudeau M, Eisenhauer EA, Higgins BP, Letendre F, Loffers WS, Norris BD, Vanderberg TA, Delorme F and Muldal AM: Docetaxel in patients with metastatic breast cancer: A phase II study of the National Canced Institute of Canada-Clinical Trials Group. J Clin Oncol 14: 422-428, 1996. (Pubitemid 126424026)
12. Valero V, Holmes F, Walters R, Theriault RL, Esparza L, Fraschini G, Fonseca GA, Bellet RE, Buzdar AN and Hortobagyi GN: Phase II trial of docetaxel: A highly new effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 13: 2886-2894, 1995.
13. Nabholtz JM, Mackey J, Smylie M, Paterson A, Noël DR, Al-Tweigeri T, Tonkin T, North S, Azli N and Riva A: Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer. J Clin Oncol 19: 314-321, 2001. (Pubitemid 32114144)
14. Polyzos A, Tsavaris N, Kosmas C, Gogas H, Vadiaka M, Markopoulos C. Giannopoulos A, Kalahanis N, Stamatiadis D, Kouraklis D, Karatzas G, Liapis C and Syrigos K: Docetaxel and epirubicin supported by granulocyte colony-stimulating factor first-line in advanced breast cancer. Antic Res 23: 2917-2924, 2003. (Pubitemid 36969835)
15. Livingston R, Ellis G, Gralow J, Williams MA, White R, McGuirt C, Adamkiewicz BB and Long CA: Dose-intensive vinorelbine with current granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 15: 1395-1400, 1997. (Pubitemid 27167371)
16. Fumoleau P, Largiller R, Clippe C, Dieras V, Orfeuvre H, Lesimple T, Culine S, Audhuy B, Serin D, Curé H, Vuillemin E, Morére JF, Montestruc F, Mouri Z and Namer M: Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer 40: 536-542, 2004. (Pubitemid 38220770)
17. Reichardt P, Von Minckwitz G, Thuss-Patience PC, Jonat W, Kölbl H, Jänicke F, Kieback DG, Kuhn W, Schindler AE, Mohrmann S, Kaufmann M and Lück HJ: Multicenter phase II study of oral capecitabine (Xeloda) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol 14: 1227-1233, 2003. (Pubitemid 37039048)
18. Razis E, Kosmidis P, Aravantinos G, Bakoyiannis G, Janinis J, Timotheadou H, Christodoulou C and Fountzilas G: Second-line chemotherapy with 5 fluorouracil and vinorelbine in anthracycline- and taxane-pretreated patients with metastatic breast cancer. Cancer Invest 22: 10-15, 2004. (Pubitemid 38523955)
19. Vassilomanolakis M, Koumakis G, Demiri M, Missitzis J, Barbounis V and Efremidis AP: Vinorelbine and cisplatin for metastatic breast cancer: a salvage regimen in patients progressing after docetaxel and anthracycline treatment. Cancer Invest 21: 497-504, 2003. (Pubitemid 37169552)
20. Margolin KA, Green S, Osborne K, Doroshow JH, Akman SA, Leong LA, Morgan RJ, Raschko JW, Somlo G and Hutchins L: Phase II trial of 5-fluorouracil and high-dose folinic acid as first- or second-line therapy for advanced breast cancer. Am J Clin Oncol 17: 175-180, 1994. (Pubitemid 24109108)
21. Rixe O, Ortuzar W, Alvarez M, Parker R, Reed E, Paull K and Fojo T: Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol 52: 1855-1865, 1996.
22. Raymond E, Buquet-Fagot C, Djelloul CJ, Mester J, Cvitkovic E, Allain P, Louvet C and Gespach C: Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancer. Anticancer Drugs 8: 876-885, 1997. (Pubitemid 27487802)
23. André T, Bensmaine MA, Louvet C, François E, Lucas V, Desseigne F, Beerblock K, Bouché O, Carola E, Merrouche Y, Morvan F, Dupont-André G and de Gramont A: Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol 17: 3560-3568, 1999. (Pubitemid 29517928)
24. Zelek L, Cottu P, Tubiana-Hulin M, Vannetzel JM, Chollet P, Misset JL, Chouaki N, Marty M, Gamelin E, Culine S, Dieras V, Mackenzie S and Spielmann M: Phase II study of oxaliplatin and fluorouracil in taxane- and anthracycline-pretreated breast cancer patients. J Clin Oncol 20: 2551-2558, 2002. (Pubitemid 34525743)
25. Pectasides D, Pectasides M, Farmakis D, Boundouroglou N, Nikolaou M, Koumpou M, Mylonakis N and Kosmas C: Oxaliplatin plus high-dose leucovorin and 5-fluorouracil in pretreated advanced breast cancer: a phase II study. Ann Oncol 14: 537-542, 2003. (Pubitemid 41295079)
26. Schüller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L, Utoh M, Mori K, Weidekamm E and Reigner B: Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 45: 291-297, 2000. (Pubitemid 30151522)
27. Van Cutsern E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, Bugat R, Findlay M, Frings S, Jahn M, McKendrick J, Osterwalder B, Perez-Manga G, Rosso R, Rougier P, Schmiegel WH, Seitz JF, Thompson P, Vieitez JM Weitzel C and Harper P; Xeloda Colorectal Cancer Study Group: Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 19: 4097-4106, 2001. (Pubitemid 33049527)
28. Talbot DC, Moiseyenko V, Van Belle S, O'Reilly SM, Alba Conejo E, Ackland S, Eisenberg P, Melnychuk D, Pienkowski T, Burger HU, Laws S and Osterwalder B: Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br J Cancer 86: 1367-1372, 2002. (Pubitemid 34548055)
29. Blum JL, Dieras V, Lo Russo PM, Horton J, Rutman O, Buzdar A and Osterwalder B: Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 92: 1759-1768, 2001.
30. Wist EA, Sommer HH, Ostenstad B, Risberg T, Bremmes Y and Mjaaland I: Oral capecitabine in anthracycline- and taxane-pretreated advanced/metastatic breast cancer. Acta Oncol 43: 186-189, 2004. (Pubitemid 38478906)
31. Xeloda (capecitabine) [product information]. Nutley NJ: Roche Pharmaceuticals, 2003.
32. Miller AB, Hoogstraten B, Staquet M and Winkler A: Reporting results of cancer treatment. Cancer 47: 207-214, 1981.
33. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10: 1-10, 1989. (Pubitemid 19099520)
34. Thus-Patience P, Minckwitz von G, Kretzchmar A, Loibl S, Schaller G, Dörken B and Reichardt P: Oxaliplatin and 5-fluorouracil for heavily pretreated metastatic breast cancer a preliminary phase II study. Anti-Cancer Drugs 14: 549-553, 2003. (Pubitemid 37083160)
35. Delozier T, Guastalla JP, Yovine A, Levy C, Chollet P, Mousseau M, Delva R, Coeffic D, Vannetzel JM, Zazzi ES, Brienza S and Cvitkovic E: A phase II study of an oxaliplatin/vinorelbine/5-fluorouracil combination in patients with anthracycline-pretreated and taxane-pretreated metastatic breast cancer. Anticancer Drugs 17: 1067-1073, 2006. (Pubitemid 44454784)
36. Delaloge S, Tubiana-Hulin M, Wardley A, Del Mastro L, Santoro A, Zambelli A, Bonetti A, Boni C, Habib F and Brienza S: A multistep randomized phase II/III trial comparing oxaliplatin (OXA)+5 fluorouracil (FU) to vinorelbine (VIN) plus FU (FUN) after taxane (T)/anthracycline (A) failure in advanced/metastatic breast cancer (MBC) patients (pts): Final results. J Clin Oncol 22: 42S-42S (660 suppl.), 2004.